Table 3.
Measure | Ethanol exposure | Duration | System | Genus | Genetic background | Method of analysis | Brain region | Effect | Duration of abstinence | Withdrawal or abstinence effects | Reference |
---|---|---|---|---|---|---|---|---|---|---|---|
AEA | 50–150 mM of ethanol | 24–72 hr | In vitro | Human | Neuroblastoma SK‐N‐SH cells | Cell and medium extract | — | ↑ | — | — | Basavarajappa & Hungund, 1999a |
100–150 mM of ethanol | 72 hr | In vitro | Rat | Wistar | Cell and medium extract | Cereb | ↑ | — | — | Basavarajappa et al., 2003 | |
7.2% v/v ethanol in liquid diet, 24‐hr access | 10–15 days | Ex vivo | Rat | Sprague–Dawley | Tissue content | AMY | — | 3 hr | ↓ | Gonzalez et al., 2002; Rubio et al., 2008 | |
CPu | — | 3 hr | ↓ | ||||||||
HyTh | — | 3 hr | None | ||||||||
Cereb | None | — | — | ||||||||
HP | None | — | — | ||||||||
Limbic forebrain | ↓ | — | — | ||||||||
Midbrain | ↓ | — | — | ||||||||
Striatum | None | — | — | ||||||||
Forced vapour inhalation | 72 hr | Ex vivo | Mouse | Swiss‐Wistar | Tissue content | Cortex | ↑ | 24 hr | None | Vinod, Yalamanchili, Xie, Cooper, & Hungund, 2006 | |
Oral chronic intermittent 5–6 g·kg−1 alternate days | 120 days | Ex vivo | Mouse | Swiss‐Wistar | Tissue content | HP | None | 40 days | ↑ | Mitrirattanakul et al., 2007 | |
Forced chronic ethanol consumption | 7 days | In vivo | Rat | Wistar | Microdialysis | NAc | None | 7–14 days | None | Ceccarini et al., 2013 | |
Alcohol‐dependent patients | Lifetime | — | Human | — | Plasma content | Plasma | ↑ | 28 days | — | Garcia‐Marchena et al., 2017 | |
Chronic intermittent ethanol vapour | 21 days every day | In vivo | Rat | Male Wistar | AEA dialysate | CeA | None | 12 hr | ↓ | Serrano et al., 2018 | |
7 days | None | ||||||||||
Chronic intermittent ethanol vapour | 10 days every day | Ex vivo | Rat | Male Sprague–Dawley | AEA | BLA | ↑ | — | — | Robinson et al., 2016 | |
NAPE‐PLD protein | BLA | None | — | — | |||||||
FAAH protein | BLA | None | — | — | |||||||
Chronic intermittent ethanol vapour | 48 days every day | Ex vivo | Rat | Male Wistar | AEA | BLA | ↓ | 3 days | ↓ | Henricks et al., 2017 | |
Female Wistar | AEA | vmPFC | — | 3 days | — | ||||||
Male Wistar | Napeld mRNA | BLA | — | 3 days | — | ||||||
Female Wistar | Napeld mRNA | vmPFC | ↓ | 3 days | ↓ | ||||||
Male Wistar | Faah mRNA | BLA | — | 3 days | — | ||||||
Female Wistar | Faah mRNA | vmPFC | — | 3 days | — | ||||||
2‐AG | 100–150 mM of ethanol | 48–72 hr | In vitro | Rat | Sprague–Dawley | Cell and medium extract | Cereb | ↑ | — | — | Basavarajappa et al., 2000 |
Oral chronic intermittent 5–6 g·kg−1 alternate days | 120 days + 2 days of withdrawal | Ex vivo | Mouse | Swiss‐Wistar | Tissue content | HP | ↑ | 40 days | ↑ | Mitrirattanakul et al., 2007 | |
7.2% v/v ethanol in liquid diet | 10–15 days | Ex vivo | Rat | Wistar | Tissue content | AMY | — | 3 hr | None | Rubio et al., 2007 | |
CPu | — | 3 hr | None | ||||||||
HyTh | — | 3 hr | |||||||||
Cereb | None | — | — | ||||||||
Cortex | None | — | — | ||||||||
HP | None | — | |||||||||
Limbic forebrain | None | — | — | ||||||||
Midbrain | ↓ | — | — | ||||||||
Striatum | None | — | — | ||||||||
Chronic intermittent ethanol vapour | 48 days every day | Ex vivo | Rat | Male Wistar | Mgll mRNA | BLA | ↓ | 3 days | ↓ | Henricks et al., 2017 | |
Female Wistar | Mgll mRNA | vmPFC | — | 3 days | — | ||||||
Male Wistar | Dagla mRNA | BLA | ↓ | 3 days | ↓ | ||||||
Female Wistar | Dagla mRNA | vmPFC | — | 3 days | — | ||||||
Male Wistar | 2‐AG | BLA | — | 3 days | — | ||||||
Female Wistar | 2‐AG | vmPFC | ↓ | 3 days | ↓ | ||||||
10 days every day | 10 days every day | Ex vivo | Rat | Male Sprague–Dawley | 2‐AG | BLA | None | — | — | Robinson et al., 2016 | |
DAGL‐α protein | BLA | None | — | — | |||||||
MAGL protein | BLA | None | — | — | |||||||
Chronic intermittent ethanol vapour | 21 days every day | In vivo | Rat | Male Wistar | Mgll mRNA | CeA | — | 12 hr | ↑ | Serrano et al., 2018 | |
Dagl mRNA | CeA | — | 12 hr | ↑ | |||||||
2‐AG dialysate | CeA | ↓ | 12 hr | ↓ | |||||||
7 days | ↓ | ||||||||||
FAAH | Chronic ethanol treatment (100–150 mM) | 72 hr | In vitro | Rat | Sprague–Dawley | Activity and EC transport | Cereb | ↓ | — | — | Basavarajappa et al., 2003 |
Forced vapour inhalation | 72 hr | Ex vivo | Mouse | Swiss‐Webster | Activity | Cortex | ↓ | — | — | Vinod et al., 2006 | |
Alcohol dependent (patients/control) | Lifetime | Post‐mortem | Human | — | Protein and activity | NAc | ↓ | — | — | Vinod et al., 2010 | |
CB1 | Continuous forced vapour inhalation | 72–96 hr | Ex vivo | Mouse | Swiss‐Webster | Binding and GTPγS binding | Whole brain | ↓ | 24 hr | None | Basavarajappa, Cooper, & Hungund, 1998a; Basavarajappa & Hungund, 1999b |
Cortex | ↓ | 24 hr | None | Vinod et al., 2006 | |||||||
HP | ↓ | ||||||||||
Striatum | ↓ | ||||||||||
Whole brain | ↓ | ||||||||||
Chronic forced vapour inhalation (intermittent) | 49 days | Ex vivo | Rat | Wistar | mRNA | Cortex | — | 3 weeks | ↑ | Rimondini et al., 2002 | |
7.2% v/v ethanol in liquid diet | 10–15 days | Ex vivo | Rat | Wistar | mRNA and binding | AMY | — | 3 hr | None | Gonzalez et al., 2002; Rubio et al., 2008 | |
None | — | — | |||||||||
CPu | — | 3 hr | None | ||||||||
None | — | — | |||||||||
HyTh | None | — | — | ||||||||
Cereb | None | — | — | ||||||||
Cortex | — | 3 hr | None | ||||||||
None | — | — | |||||||||
HP | None | — | — | ||||||||
NAc | None | — | — | ||||||||
GP | — | 3 hr | ↓ | ||||||||
SN | — | 3 hr | ↓ | ||||||||
Forced consumption of ethanol (10%, v/v) | 52 days | Ex vivo | Rat | Wistar | mRNA | CPu | ↓ | — | — | Ortiz et al., 2004 | |
Cortex | None | ||||||||||
HP | Region dependent | ||||||||||
HyTh | ↓ | — | — | ||||||||
Operant ethanol self‐administration | 10 days | Ex vivo | Rat | msP | mRNA | AMY | None | — | — | Cippitelli et al., 2005 | |
CPu | ↓ | ||||||||||
Cortex | None | ||||||||||
HP | None | ||||||||||
Alcohol dependent (patients/control) | Lifetime | Post‐mortem | Human | — | Protein and GTPγS | NAc | ↓ | — | — | Vinod et al., 2010 | |
Chronic, 5–6 g·kg−1 every other day (intermittent) | 120 days | Ex vivo | Rat | Sprague–Dawley | Protein and mRNA | HP | ↓ | 40 days | ↑ | Mitrirattanakul et al., 2007 | |
Twice daily 4 g·kg−1 i.p. | 10 days | Ex vivo | Mouse | C57BL/6J | Protein | Cereb | None | — | — | Pava et al., 2012 | |
Cortex | None | — | — | ||||||||
HP | None | — | — | ||||||||
HyTh | ↓ | — | — | ||||||||
NAc | None | — | — | ||||||||
Striatum | None | — | — | ||||||||
VTA | ↓ | — | — | ||||||||
Forced chronic ethanol consumption | 7 days | In vivo | Rat | Wistar | PET imaging | HP | ↓ binding | 7–14 days | ↑ binding | Ceccarini et al., 2013 | |
CPu | ↓ binding | ↑ binding | |||||||||
OFC | — | ↓ binding | |||||||||
Chronic intermittent ethanol vapour | 10 days every day | Ex vivo | Rat | Male Sprague–Dawley | Protein | BLA | ↓ | — | — | Robinson et al., 2016 |
Abbreviations: 2‐AG, 2‐arachidonyl glycerol; AEA, anandamide; AMY, amygdala; BLA, basolateral amygdala; CB1, cannabinoid receptor 1; CeA, central amygdala; Cereb, cerebellum; CPu, caudate putamen; DAGL, DAG lipase; FAAH, fatty acid amide hydrolase; GP, globus pallidus; HP, hippocampus; HyTh, hypothalamus; MAGL, monoacylglycerol lipase; msP, marchigian Sardinian alcohol‐preferring; NAc, nucleus accumbens; NAPE‐PLD, N‐acylphosphatidylethanolamine‐specific PLD; OFC, orbitofrontal cortex; PFC, prefrontal cortex; SN, substantia nigra; vmPFC, ventromedial prefrontal cortex; VTA, ventral tegmental area.